Nanotrope Awarded NASA Phase 2 Grant to Advance Nanoscale Drug Delivery
"Nanotrope is especially excited to have won the NASA SBIR grant which is awarded to a select group of businesses," said Dr. Donald Ackley president and CEO for Nanotrope Inc. "With this funding from NASA, our research will allow us to rapidly move forward on applying nanodroplet technology toward targeted drug delivery."
“With this funding from NASA, our research will allow us to rapidly move forward on applying nanodroplet technology toward targeted drug delivery.”
Nanotrope's nanoscale droplet technology has positive implications for NASA, the pharmaceutical industry, and patients. In a complex process combining microfluidics and nanotechnology, Nanotrope's nanodroplet generator technology can produce drug "containers" that carry specific delivery instructions that enable the targeting of diseased cells and organs. The innovation of these high-precision drug formulations will allow drug companies to develop more effective and safer drugs. Patients will benefit from targeted drugs as the new drugs would affect only the unhealthy cells or organs, versus all-over drug treatments - such as chemotherapy - which can damage otherwise healthy areas.
Founded in 2004, Nanotrope Inc. aims to commercialize nanoscale droplet technology developed at the University of California, Irvine. The droplet technology provides high-precision, digital control of biochemical processes at the nanoscale. As protein and antibody drugs proliferate in the biopharmaceutical pipeline, there is a need for new drug formulations and delivery protocols. Nanotrope's unique droplet chemistry enables unique delivery formulations, enhancing safety and efficacy of new drugs - shortening the approval cycle, and providing new benefits for patients. Nanotrope headquarters are at 3030 Bunker Hill St., Suite 111b, San Diego, CA 92109 and can be reached at 858-270-7992. Additional information about the company and its technology is available at http://www.Nanotrope.com